Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden

被引:5
作者
Kagstrom, E. [1 ]
Lannergard, A. [1 ]
El Khosht, J. [2 ]
Lorelius, P. [2 ]
Manflod, J. [2 ]
Stromdahl, S. [1 ]
机构
[1] Uppsala Univ, Dept Med Sci, Infect Dis, Uppsala, Sweden
[2] Reg Uppsala, Needle & Syringe Program Uppsala, Nara Vard Och Halsa, Uppsala, Sweden
关键词
Hepatitis C; People who inject drugs; Needle exchange program; Harm reduction; Injection drug use; Injection risk behavior; Reinfection; Needle syringe program; ACTING ANTIVIRAL AGENTS; GENOTYPE DISTRIBUTION; INFECTION; EPIDEMIOLOGY; TRANSMISSION;
D O I
10.1186/s12954-023-00806-w
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundThe World Health Organization has set a goal to reach world elimination of hepatitis C virus (HCV) by 2030. Needle and syringe programs (NSP) for people who inject drugs (PWID) are crucial to achieve this goal. The NSP in Uppsala, Sweden, was opened in 2016 and has since 2018 provided HCV treatment for PWID. The aim of this study was to investigate HCV prevalence, risk factors and treatment uptake and outcome in NSP participants.MethodsData from 450 PWID registered at the Uppsala NSP between 2016-11-01 and 2021-12-31 were collected from the national quality registry InfCare NSP. Data from the 101 PWID treated for HCV at the Uppsala NSP were collected through patient journal review. Descriptive and inferential analysis was performed. Ethical approval was obtained from the Ethical Review Board in Uppsala (dnr 2019/00215).ResultsThe mean age was 35 years. 75% were males (336/450), and 25% were females (114/450). The overall HCV prevalence was 48% (215/450) with a declining trend over time. Factors associated with a higher risk of HCV were older age at registration (OR 1.025, 95% CI 1.004-1.046), lower age at injection drug debut (OR 0.963, 95% CI 0.932-0.996), lower education level (OR 1.829, 95% CI 1.185-2.821) and higher number of total visits at the NSP (OR 1.005, 95% CI 1.001-1.009). The overall HCV treatment uptake was 47% (101/215), of which 77% (78/101) completed HCV treatment. The HCV treatment compliance was 88% (78/89). 99% (77/78) were cured with a sustained virologic response 12 weeks after completed treatment. The reinfection rate over the study period was 9/77 (11.7%); all were male with mean age of 36.ConclusionsHCV prevalence, treatment uptake and treatment outcome have improved since the opening of the Uppsala NSP. However, further measures are needed to reach the HCV elimination goal. Outreach HCV treatment programs for PWID should be explored and evaluated in combination with further implementation of low-threshold programs.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] European Centre for Disease Prevention and Control (ECDC), 2021, SUSTAINABLE DEV GOAL
  • [12] Folkhalsomyndigheten [The Public Health Agency of Sweden], HEP C SJUKD
  • [13] Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
    Fraser, Hannah
    Martin, Natasha K.
    Brummer-Korvenkontio, Henrikki
    Carrieri, Patrizia
    Dalgard, Olav
    Dillon, John
    Goldberg, David
    Hutchinson, Sharon
    Jauffret-Roustide, Marie
    Kaberg, Martin
    Matser, Amy A.
    Maticic, Mojca
    Midgard, Havard
    Mravcik, Viktor
    Ovrehus, Anne
    Prins, Maria
    Reimer, Jens
    Robaeys, Geert
    Schulte, Bernd
    van Santen, Daniela K.
    Zimmermann, Ruth
    Vickerman, Peter
    Hickman, Matthew
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 (03) : 402 - 411
  • [14] Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights
    Gotte, Matthias
    Feld, Jordan J.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (06) : 338 - 351
  • [15] Global epidemiology and genotype distribution of the hepatitis C virus infection
    Gower, Erin
    Estes, Chris
    Blach, Sarah
    Razavi-Shearer, Kathryn
    Razavi, Homie
    [J]. JOURNAL OF HEPATOLOGY, 2014, 61 : S45 - S57
  • [16] Direct-acting antiviral agents for HCV infection affecting people who inject drugs
    Grebely, Jason
    Hajarizadeh, Behzad
    Dore, Gregory J.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (11) : 641 - 651
  • [17] Hepatitis C outreach project and cross-sectional epidemiology in high-risk populations in Trondheim, Norway
    Hannula, Raisa
    Soderholm, Jonas
    Svendsen, Therese
    Skaland, Maja
    Nordbo, Svein A.
    Steinum, Harald
    Damas, Jan K.
    [J]. THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2021, 8
  • [18] Significant decrease in injection risk behaviours among participants in a needle exchange programme
    Kaberg, Martin
    Karlsson, Niklas
    Discacciati, Andrea
    Widgren, Katarina
    Weiland, Ola
    Ekstrom, Anna Mia
    Hammarberg, Anders
    [J]. INFECTIOUS DISEASES, 2020, 52 (05) : 336 - 346
  • [19] Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program
    Kaberg, Martin
    Hammarberg, Anders
    Lidman, Christer
    Weiland, Ola
    [J]. INFECTIOUS DISEASES, 2017, 49 (10) : 728 - 736
  • [20] Risk behaviour determinants among people who inject drugs in Stockholm, Sweden over a 10-year period, from 2002 to 2012
    Karlsson, Niklas
    Santacatterina, Michele
    Kall, Kerstin
    Hagerstrand, Maria
    Wallin, Susanne
    Berglund, Torsten
    Ekstrom, Anna Mia
    [J]. HARM REDUCTION JOURNAL, 2017, 14